FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($2.55), $0.06 better than the analyst estimate of ($2.61). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $7.65 million.
Vlad Coric, M.D. Chief Executive Officer, commented, "This has been an... More

